Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1398-9995|70|6|707-710

ISSN： 0105-4538

Source： ALLERGY, Vol.70, Iss.6, 2015-06, pp. : 707-710

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Safety of Allergen Specific Sublingual Immunotherapy

By  

Current Drug Safety, Vol. 2, Iss. 2, 2007-05 ,pp. : 117-123

Bentham Science Publishers

Access to resources Recommend Favorite

Practice and safety of allergen‐specific immunotherapy for allergic rhinitis in the UK national health service: A report of “real world” clinical practice

By  

CLINICAL & EXPERIMENTAL ALLERGY, Vol. 48, Iss. 1, 2018-01 ,pp. : 89-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical contraindications to allergen immunotherapy: an EAACI position paper

By  

ALLERGY, Vol. 70, Iss. 8, 2015-08 ,pp. : 897-909

John Wiley & Sons Inc

Access to resources Recommend Favorite

Requirement of MyD88 and Fas pathways for the efficacy of allergen‐free immunotherapy

By  

ALLERGY, Vol. 70, Iss. 3, 2015-03 ,pp. : 275-284

John Wiley & Sons Inc

Access to resources Recommend Favorite

The safety of self‐administered allergen immunotherapy during the buildup and maintenance phases

By  

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, Vol. 5, Iss. 2, 2015-02 ,pp. : 149-156

John Wiley & Sons Inc

Access to resources Recommend Favorite